Retatrutide Price: $125 a Vial vs $199 a Month for Wegovy

The retatrutide price at the supplier we link is $99.00 for a 10 mg vial and $250.00 for a 30 mg vial before any discount, and the code PEPTIDEDECK halves both. So the figures that reach your card are $49.50 and $125.00. Everything else on this page is the arithmetic and the caveats sitting behind those two numbers.

Both list prices are themselves reductions, from $149.99 and $299.99. That matters for one reason only: when you compare a discounted price against another seller's headline, you are comparing two numbers that were each set by the seller, and neither is a market rate. Peptide pricing has no reference point equivalent to a drug list price, so the comparison you can trust is the one you do yourself, in milligrams.

We earn a commission if you buy through our link, which is set out in full on our affiliate disclosure page. It does not change the numbers above, and it is the reason we publish the list prices next to the discounted ones rather than only the flattering half.

Vial prices are not comparable across strengths, which is where most retatrutide cost comparisons go wrong. A 10 mg vial at $49.50 works out at $4.95 per milligram. A 30 mg vial at $125.00 works out at $4.17. The larger vial is 15% cheaper per milligram, and that gap is the single largest lever on this page.

The division is worth doing on every listing you look at, because sellers quote in whatever unit makes them look best: per vial, per kit, per gram, sometimes per box of five. Convert to price per milligram in your own currency and the ranking of a shortlist often reverses.

There is a third unit that appears in research listings, cost per research unit or per reconstituted milliliter, and it is the one to ignore when comparing suppliers. It depends entirely on how much bacteriostatic water gets added in the laboratory, which is your decision and not a property of the product. Two identical vials can produce wildly different per-milliliter figures.

A quick sanity check on any retatrutide price you find elsewhere: multiply the per-milligram figure by 30 and see whether the result is close to $125.00. Well above and you are paying for the packaging. Far below and something has been left out of the operation, usually the third-party testing, the domestic warehouse, or both. Neither result is proof of anything by itself, but a large gap is a question worth answering before you pay.

Search volume for retatrutide cost without insurance is high, and the honest answer is that the phrase imports an assumption that does not hold. Insurance covers products with a marketing authorization, an NDC number and a place on a formulary. Retatrutide has none of those, in any market. It is an investigational compound from Eli Lilly, still running through the Phase 3 TRIUMPH program, which you can track on ClinicalTrials.gov.

So there is no covered price and no cash price, because there are only two prices in the world for approved medicines and retatrutide sits in neither. There is a research-material price, set by a supplier, paid in full by you. No plan will reimburse it, no HSA or FSA claim will survive scrutiny, and no manufacturer savings card exists, because the manufacturer is not selling it.

That is a cleaner situation than it sounds, in one narrow respect. When we work through what GLP-1 programs cost by state, half the complexity is coverage rules, prior authorizations and step therapy. None of that applies here. What you see is the whole price. What you give up in exchange is everything that coverage apparatus exists to provide.

Two things move the total beyond the vial price. Bulk tiers take a further 3%, 5% or 10% off the list price at three, five and ten vials, and shipping is free over $250. Both are simple, and both are easy to misread.

The shipping threshold is measured against your order total, and a 50% code moves that total. A single 30 mg vial at $125.00 sits under the line even though its list price does not. Two vials clear it. If you were planning a single-vial order and shipping is charged, add the shipping cost into your per-milligram figure before you decide the price was good.

Whether a bulk tier and the discount code combine is a question the checkout answers, not one we will guess at. Put the order together both ways, with the code alone and with the tier, and compare the two final totals on screen. The version that wins on paper is not always the version that wins in the cart, and the only reliable number is the one on the confirmation page.

One caution about buying deep on a bulk tier. Lyophilized peptide is stable in a fridge but not indefinitely, and every extra vial you buy to shave 3% off the retatrutide price is a vial you are betting you will still want in a year. Suppliers change, batches change, and a certificate that matched your first vial does not describe the tenth. Buying the quantity you need at the price on the day is usually the better trade than buying the discount.

This is the part a price page usually skips. The retatrutide price is low because the purchase is small, not because someone found an efficiency. You are buying a lyophilized vial of research material and nothing else is included in the transaction.

No prescriber reviews whether the compound suits you. No pharmacist checks it against anything else you take. There is no approved label, no medication guide, no adverse event reporting route, and no clinical follow-up. If something goes wrong, the parties who answer are the vendor, under its own written policy, and your card issuer. That is the complete list.

The documentation you do get is worth naming, because it is the only formal assurance in the deal. Ascension publishes two independent certificates of analysis per batch rather than the single certificate that is normal in this market: Kovera Labs, batches 03-05260628 and 43-05260628, tested May 26, 2026, and MZ Biolabs, batches 03-01260229 and 43-01260229, tested February 6, 2026. Batch numbers are printed, so you can match them against the vial that arrives. Our sibling guide on judging a retatrutide source covers what to do if they do not match.

Most readers who reach this page have already been quoted a monthly figure by a telehealth clinic, so the comparison is the useful part. Across the programs we track, entry pricing runs from roughly $99 for a first month to around $349 a month for brand tirzepatide through the manufacturer's own direct channel, with self-pay Wegovy at $199 a month sitting in between. Against that, $125.00 for a 30 mg vial looks like a rounding error.

It is not the same purchase, and the table sets out why. A program price buys a clinician, a licensed pharmacy, an FDA-approved product with a label, dose escalation support, and a regulator standing behind all of it. A vial price buys a vial. The gap between the two numbers is almost exactly the cost of that apparatus.

There is one more asymmetry that no table captures. For semaglutide and tirzepatide, the prescription route and the research route both exist, so a price comparison is a genuine choice. For retatrutide the prescription route does not exist at any price, which means this is not really a cheaper option, it is the only option that exists. If a supervised program would meet your goal, our guide to paying less for Zepbound is the better page to read next.

If you remember one figure from this page, make it $4.17 per milligram. It survives changes in vial size, it exposes the difference between a real discount and a rearranged list price, and it is the only number that lets you compare two suppliers who quote in different units.

It also settles the question people usually arrive with, which is whether the retatrutide price they were shown is fair. Fair is not a concept this market supports, because there is no reference price, no negotiated rate and no regulator watching. What you can establish is whether a number is consistent with the cost of running a supplier that tests every batch and holds domestic stock. $4.17 per milligram is.

The second number worth keeping is the one from your telehealth quote, because it tells you what you are declining rather than what you are saving. Our reviews of 35 programs put those quotes side by side if you want to check the one you were given before deciding.

And keep the third number in view, which is zero: the number of regulators that have approved retatrutide for anyone to use. The Phase 2 results published in 2023 are why demand arrived years ahead of approval, not evidence that the wait is unnecessary. Price is the easiest thing to research about this compound, and the least important.